Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aerie Pharmaceuticals (NQ: AERI )

15.25 UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 18, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 15.25
Bid (Size) 15.24 (31)
Ask (Size) 15.25 (201)
Prev. Close 15.25
Today's Range 15.25 - 15.25
52wk Range 4.810 - 15.37
Shares Outstanding 47,233,646
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aerie Pharmaceuticals's Return On Capital Employed Overview
 
Via Benzinga
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
From Alcon Inc. Investors
Via Business Wire

Performance

YTD
+104.21%
+104.21%
1 Month
+0.20%
+0.20%
3 Month
+0.99%
+0.99%
6 Month
+208.08%
+208.08%
1 Year
+50.99%
+50.99%

More News

Read More
AiViva Reports That Their Promising New Treatment For Wet AMD Is Soon To Be Ready For Clinical Trials
Via Benzinga
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Aerie Pharmaceuticals, Inc.
Via Business Wire
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
From Kahn Swick & Foti, LLC
Via Business Wire
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
Via MarketBeat
Topics Stocks
Exposures US Equities
Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year
Via Investor's Business Daily
Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022
Via Benzinga
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
From Kahn Swick & Foti, LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2022
Via Benzinga
Aerie Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
AERI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Aerie Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
Why XPeng Shares Traded Lower By Around 11%; Here Are 77 Biggest Movers From Yesterday
Via Benzinga
Macy's, Palo Alto Networks And Other Big Gainers From Tuesday
Via Benzinga
Alcon May Struggle To Meet 2023 Margin Targets With This Latest Acquisition, Says This Analyst
Via Benzinga
Dow Drops Over 100 Points; Aerie Pharmaceuticals Shares Spike Higher
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Stocks Cut Lower As Dow Sheds Another Triple Digits
Via Talk Markets
Nasdaq Turns Lower; Crude Oil Rises Sharply
Via Benzinga
Why Windtree Therapeutics Is Trading Higher By Over 60%, Here Are 61 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Is Ocugen (OCGN) Stock Climbing Higher Today?
Via InvestorPlace
Aerie Pharmaceuticals (NASDAQ: AERI) Enters into Agreement to be Acquired by Alcon (NYSE: ALC) for $770 Million
Via Spotlight Growth
INTC Stock Alert: What to Know as Intel Co-Invests in Arizona Chip Factories
Via InvestorPlace
Why Is Aerie Pharmaceuticals (AERI) Stock Up 35% Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.